Literature DB >> 24374148

Evolution of HIV treatment guidelines in high- and low-income countries: converging recommendations.

Eugene T Richardson1, Philip M Grant1, Andrew R Zolopa2.   

Abstract

Over the past 15 years, antiretroviral treatment guidelines for HIV infection have evolved significantly, reflecting the major advances in this therapeutic area. Evidenced-based recommendations have largely replaced expert opinion, while diagnostic monitoring and therapeutic interventions have become more sophisticated and effective. Just 10 years ago, there was a marked difference in access to antiretroviral therapy for patients in wealthy and impoverished countries. The increasing availability of therapy across the globe, however, has made it possible for international guidelines to resemble more closely those in high-income countries. This article compares the evolution of antiretroviral therapy treatment guidelines from the United States Department of Health and Human Services and the World Health Organization, focusing on when to initiate ART in asymptomatic patients and in those with an opportunistic infection; initial regimens in the general population and in special populations; when to change and what to change; and laboratory monitoring.
Copyright © 2014. Published by Elsevier B.V.

Entities:  

Keywords:  ART-treatment; Guidelines; HIV-treatment

Mesh:

Substances:

Year:  2013        PMID: 24374148      PMCID: PMC4193472          DOI: 10.1016/j.antiviral.2013.12.007

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  47 in total

1.  Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.

Authors:  David A Cooper; Jayvant Heera; James Goodrich; Margaret Tawadrous; Michael Saag; Edwin Dejesus; Nathan Clumeck; Sharon Walmsley; Naitee Ting; Eoin Coakley; Jacqueline D Reeves; Gustavo Reyes-Teran; Mike Westby; Elna Van Der Ryst; Prudence Ive; Lerato Mohapi; Horacio Mingrone; Andrzej Horban; Frances Hackman; John Sullivan; Howard Mayer
Journal:  J Infect Dis       Date:  2010-03-15       Impact factor: 5.226

2.  Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa.

Authors:  Azure T Makadzange; Chiratidzo E Ndhlovu; Kudakwashe Takarinda; Michael Reid; Magna Kurangwa; Philimon Gona; James G Hakim
Journal:  Clin Infect Dis       Date:  2010-06-01       Impact factor: 9.079

Review 3.  The evolution of HIV treatment guidelines: current state-of-the-art of ART.

Authors:  Andrew R Zolopa
Journal:  Antiviral Res       Date:  2009-10-31       Impact factor: 5.970

4.  Factors associated with mother-to-child transmission of HIV-1 despite a maternal viral load <500 copies/ml at delivery: a case-control study nested in the French perinatal cohort (EPF-ANRS CO1).

Authors:  Roland Tubiana; Jerome Le Chenadec; Christine Rouzioux; Laurent Mandelbrot; Karima Hamrene; Catherine Dollfus; Albert Faye; Constance Delaugerre; Stephane Blanche; Josiane Warszawski
Journal:  Clin Infect Dis       Date:  2010-02-15       Impact factor: 9.079

5.  Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.

Authors:  Christine Katlama; Richard Haubrich; Jacob Lalezari; Adriano Lazzarin; José V Madruga; Jean-Michel Molina; Mauro Schechter; Monika Peeters; Gaston Picchio; Johan Vingerhoets; Brian Woodfall; Goedele De Smedt
Journal:  AIDS       Date:  2009-11-13       Impact factor: 4.177

6.  Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.

Authors:  Jeffrey L Lennox; Edwin DeJesus; Adriano Lazzarin; Richard B Pollard; Jose Valdez Ramalho Madruga; Daniel S Berger; Jing Zhao; Xia Xu; Angela Williams-Diaz; Anthony J Rodgers; Richard J O Barnard; Michael D Miller; Mark J DiNubile; Bach-Yen Nguyen; Randi Leavitt; Peter Sklar
Journal:  Lancet       Date:  2009-08-03       Impact factor: 79.321

7.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  M A Fischl; D D Richman; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; R T Schooley
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

8.  Maraviroc for previously treated patients with R5 HIV-1 infection.

Authors:  Roy M Gulick; Jacob Lalezari; James Goodrich; Nathan Clumeck; Edwin DeJesus; Andrzej Horban; Jeffrey Nadler; Bonaventura Clotet; Anders Karlsson; Michael Wohlfeiler; John B Montana; Mary McHale; John Sullivan; Caroline Ridgway; Steve Felstead; Michael W Dunne; Elna van der Ryst; Howard Mayer
Journal:  N Engl J Med       Date:  2008-10-02       Impact factor: 91.245

9.  Effect of early versus deferred antiretroviral therapy for HIV on survival.

Authors:  Mari M Kitahata; Stephen J Gange; Alison G Abraham; Barry Merriman; Michael S Saag; Amy C Justice; Robert S Hogg; Steven G Deeks; Joseph J Eron; John T Brooks; Sean B Rourke; M John Gill; Ronald J Bosch; Jeffrey N Martin; Marina B Klein; Lisa P Jacobson; Benigno Rodriguez; Timothy R Sterling; Gregory D Kirk; Sonia Napravnik; Anita R Rachlis; Liviana M Calzavara; Michael A Horberg; Michael J Silverberg; Kelly A Gebo; James J Goedert; Constance A Benson; Ann C Collier; Stephen E Van Rompaey; Heidi M Crane; Rosemary G McKaig; Bryan Lau; Aimee M Freeman; Richard D Moore
Journal:  N Engl J Med       Date:  2009-04-01       Impact factor: 91.245

10.  Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial.

Authors:  Andrew Zolopa; Janet Andersen; William Powderly; Alejandro Sanchez; Ian Sanne; Carol Suckow; Evelyn Hogg; Lauren Komarow
Journal:  PLoS One       Date:  2009-05-18       Impact factor: 3.240

View more
  9 in total

Review 1.  When Global ART Budgets Cannot Cover All Patients, Who Should Be Eligible?

Authors:  Yi Zhang; Till Bärnighausen; Nir Eyal
Journal:  J Acquir Immune Defic Syndr       Date:  2019-06-01       Impact factor: 3.731

2.  Simultaneous quantification of intracellular lamivudine and abacavir triphosphate metabolites by LC-MS/MS.

Authors:  Nagsen Gautam; Zhiyi Lin; Mary G Banoub; Nathan A Smith; Audai Maayah; JoEllyn McMillan; Howard E Gendelman; Yazen Alnouti
Journal:  J Pharm Biomed Anal       Date:  2018-02-20       Impact factor: 3.935

3.  Association of Immunosuppression and Human Immunodeficiency Virus (HIV) Viremia With Anal Cancer Risk in Persons Living With HIV in the United States and Canada.

Authors:  Raúl U Hernández-Ramírez; Li Qin; Haiqun Lin; Wendy Leyden; Romain S Neugebauer; Keri N Althoff; Nancy A Hessol; Chad J Achenbach; John T Brooks; M John Gill; Surbhi Grover; Michael A Horberg; Jun Li; W Christopher Mathews; Angel M Mayor; Pragna Patel; Charles S Rabkin; Anita Rachlis; Amy C Justice; Richard D Moore; Eric A Engels; Michael J Silverberg; Robert Dubrow
Journal:  Clin Infect Dis       Date:  2020-03-03       Impact factor: 9.079

4.  Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada.

Authors:  Robert Dubrow; Li Qin; Haiqun Lin; Raúl U Hernández-Ramírez; Romain S Neugebauer; Wendy Leyden; Keri N Althoff; Chad J Achenbach; Nancy A Hessol; Sharada P Modur; Gypsyamber DʼSouza; Ronald J Bosch; Surbhi Grover; Michael A Horberg; Mari M Kitahata; Angel M Mayor; Richard M Novak; Charles S Rabkin; Timothy R Sterling; James J Goedert; Amy C Justice; Eric A Engels; Richard D Moore; Michael J Silverberg
Journal:  J Acquir Immune Defic Syndr       Date:  2017-08-01       Impact factor: 3.731

5.  Efficient semiparametric inference for two-phase studies with outcome and covariate measurement errors.

Authors:  Ran Tao; Sarah C Lotspeich; Gustavo Amorim; Pamela A Shaw; Bryan E Shepherd
Journal:  Stat Med       Date:  2020-11-03       Impact factor: 2.373

6.  Contribution of human immunodeficiency virus type 1 minority variants to reduced drug susceptibility in patients on an integrase strand transfer inhibitor-based therapy.

Authors:  Richard M Gibson; Jan Weber; Dane Winner; Michael D Miller; Miguel E Quiñones-Mateu
Journal:  PLoS One       Date:  2014-08-11       Impact factor: 3.240

Review 7.  Autism screening and diagnosis in low resource settings: Challenges and opportunities to enhance research and services worldwide.

Authors:  Maureen S Durkin; Mayada Elsabbagh; Josephine Barbaro; Melissa Gladstone; Francesca Happe; Rosa A Hoekstra; Li-Ching Lee; Alexia Rattazzi; Jennifer Stapel-Wax; Wendy L Stone; Helen Tager-Flusberg; Audrey Thurm; Mark Tomlinson; Andy Shih
Journal:  Autism Res       Date:  2015-10-06       Impact factor: 5.216

Review 8.  RNA Interference Therapies for an HIV-1 Functional Cure.

Authors:  Robert J Scarborough; Anne Gatignol
Journal:  Viruses       Date:  2017-12-27       Impact factor: 5.048

9.  Implementing parallel spreadsheet models for health policy decisions: The impact of unintentional errors on model projections.

Authors:  Stephanie L Bailey; Rose S Bono; Denis Nash; April D Kimmel
Journal:  PLoS One       Date:  2018-03-23       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.